Gilead Sciences, Inc. holds a concentrated book of 6 stocks worth $2.1B as of Q1 2026 (disclosed May 8, 2026, a ~38-day 13F lag). This quarter they trimmed Xilio Therapeutics Inc. Their largest long position is Arcellx Inc at 36% of the equity book. Cloning the disclosed picks since 2025 would be +247% (+129.9%/yr). That is a simulation of the disclosed long book, not audited returns.
Following at the filing date actually beat the quarter-end book by 109.3 points over this window.
Growth of $10,000 cloning Gilead Sciences, Inc.'s disclosed long 13F book, rebalanced on each filing date (so it reflects each quarter's actual reporting lag, ~38 days for the latest filing, with no look-ahead), total-return basis (dividends reinvested), derived from end-of-day prices. “Their reported book” values the same picks from quarter-end, before they were public. S&P 500 is SPY total return over the same window. Excludes shorts, cash, options and non-13F holdings. Not investment advice.
Top-heavy: concentrated book
Share of the disclosed book in its largest positions. A higher top-5 share means a more concentrated, higher-conviction portfolio.
63% mapped to company sectors
Direct operating-company sectors from our SIC-based security master. ETF/fund and unclassified holdings stay visible separately; this is not ETF look-through exposure.
Estimated $ traded · quarter-end prices, no cost basis
No buys this quarter.
Other tracked managers holding the same core names as Gilead Sciences, Inc.
| Manager / fund | Shared names | Their $ in those |
|---|---|---|
| BlackRock, Inc. | 5 / 6 | $804.4M |
| GOLDMAN SACHS GROUP INC | 5 / 6 | $176.5M |
| GEODE CAPITAL MANAGEMENT, LLC | 5 / 6 | $174.5M |
| MORGAN STANLEY | 5 / 6 | $140.5M |
| JPMORGAN CHASE & CO | 5 / 6 | $71.3M |
| BANK OF AMERICA CORP /DE/ | 5 / 6 | $67.3M |
| UBS Group AG | 5 / 6 | $37.7M |
| Ken Griffin | 5 / 6 | $36.2M |
Ranked by how many of Gilead Sciences, Inc.'s top 6 disclosed names each fund also holds: a cross-fund conviction signal from the latest 13F of every tracked manager.
Bars show each stock's share of the portfolio. Click a row for its position history.
| # | Security | Value | Shares | % Port | Last move | History |
|---|---|---|---|---|---|---|
| 1 | Arcellx Inc COM | $771.7M | 6.72M | 36.4% | —Held | |
| 2 | Arcus Biosciences Inc COM | $678.8M | 31.42M | 32.1% | —Held | |
| 3 | Galapagos NV SPON ADR | $501.2M | 16.71M | 23.7% | —Held | |
| 4 | Assembly Biosciences Inc COM NEW | $125.0M | 4.51M | 5.9% | —Held | |
| 5 | Kyverna Therapeutics Inc COM | $35.6M | 4.13M | 1.7% | —Held | |
| 6 | Xilio Therapeutics Inc COM | $5.5M | 650.4K | 0.3% | ▼−93% Reduced · −8.5M sh |
The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
This fund page is the Follow view. The Build view lets your agent pull holdings, quarter changes, overlap, and source filings through API or MCP.
curl -H "Authorization: Bearer YOUR_API_KEY" \ "https://arkolith.com/api/v1/funds/882095/holdings"
Use Arkolith to show GILEAD SCIENCES, INC.'s latest holdings, largest changes, and filing provenance.
As-of date vs the date the SEC received each filing
| Quarter | As of | Filed | Positions | Value | Form |
|---|---|---|---|---|---|
| Q1 2026 | Mar 31, 2026 | May 8, 2026 | 6 | $2.1B | 13F-HR |
| Q4 2025 | Dec 31, 2025 | Feb 12, 2026 | 6 | $1.9B | 13F-HR |
| Q3 2025 | Sep 30, 2025 | Nov 13, 2025 | 9 | $1.8B | 13F-HR |
| Q2 2025 | Jun 30, 2025 | Aug 14, 2025 | 14 | $1.3B | 13F-HR |
| Q1 2025 | Mar 31, 2025 | May 13, 2025 | 14 | $1.2B | 13F-HR |
| Q4 2024 | Dec 31, 2024 | Feb 13, 2025 | 16 | $1.6B | 13F-HR |
Holdings from SEC EDGAR 13F-HR filings, updated quarterly, filed up to 45 days after quarter-end. Public domain. The book and weighting are long equity only; disclosed put/call options are listed separately and excluded from those totals. The performance line is a simulation of the disclosed long book, not an audited return.